OCULAR THERAPEUTIX, INC
Ocular Therapeutix is an integrated biopharmaceutical company developing and commercializing eye treatments using its ELUTYX bioresorbable hydrogel technology. Its products and candidates incorporate therapeutic agents into the hydrogel for local, programmed drug release. The commercial product DEXTENZA is an FDA-approved corticosteroid for ocular inflammation and pain following ophthalmic surgery and for ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s investigational candidate AXPAXLI is an axitinib hydrogel delivered by intravitreal injection and is being evaluated in Phase 3 programs for wet age-related macular degeneration and diabetic retinal disease. OTX-TIC, a travoprost intracameral hydrogel candidate for open-angle glaucoma or ocular hypertension, has completed a Phase 2 trial. Ocular Therapeutix makes money by commercializing DEXTENZA. It holds worldwide exclusive commercial rights to the core technology underlying its product candidates, with a collaboration and license agreement with AffaMed Therapeutics for DEXTENZA and OTX-TIC in certain Asian geographies. The company is headquartered in Bedford, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $OCUL in the last 7 days.
Ocular Therapeutix (OCUL) presented at Chardan's conference, highlighting its wet AMD drug AXPAXLI. The company reported SOL-1 trial success, a clear FDA path, and $600M cash runway. Management emphasized AXPAXLI's maintenance-therapy model and competitive advantages. OCUL shares rose 4.13% to $6.55.
H.C. Wainwright reiterated a Buy rating on Ocular Therapeutix (OCUL) with a $25.00 price target, citing undervaluation. The stock is near its 52-week low at $6.29. The firm addressed EyePoint Pharmaceuticals' failed trial, noting differences in drug pharmacology and trial design. UBS initiated coverage with a Buy rating, projecting $3.3B in sales by 2035. RBC Capital reiterated its Outperform rating. OCUL plans to submit an NDA for Axpaxli in Q4 2026.
Needham reaffirmed a Buy rating on Ocular Therapeutix (OCUL) with an $18 price target, suggesting a 162% upside from the Oct 16 close of $6.87. The firm highlights Axpaxli's strong market position and promising clinical data, including extended dosing intervals of 9-12 months.
Recent OCUL coverage spans financial news, market movers and corporate actions.
In the last 30 days, OCUL insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($234K). The most active reporter was Kaiser Peter, Chief Development Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive Phase 2 data and regulatory clarity could lift the stock.
Potential upside if the buy rating spurs buying interest ahead of the NDA submission.
Needham reaffirmed a Buy rating on Ocular Therapeutix (OCUL) with an $18 price target, suggesting a 162% upside from the Oct 16 close of $6.87. The firm highlights Axpaxli's strong market position and promising clinical data, including extended dosing intervals of 9-12 months.
The resignation removes a senior strategist, potentially affecting Ocular Therapeutix's strategic direction.
The departure of a senior executive may raise uncertainty about the company's strategic direction.
AlphAI scores every news story that mentions OCUL with an AI model for sentiment and relevance, and aggregates insider trades from OCULAR THERAPEUTIX, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Ocular Therapeutix (OCUL) presented at Chardan's conference, highlighting its wet AMD drug AXPAXLI. The company reported SOL-1 trial success, a clear FDA path, and $600M cash runway. Management emphasized AXPAXLI's maintenance-therapy model and competitive advantages. OCUL shares rose 4.13% to $6.55.
2 min readH.C. Wainwright reiterated a Buy rating on Ocular Therapeutix (OCUL) with a $25.00 price target, citing undervaluation. The stock is near its 52-week low at $6.29. The firm addressed EyePoint Pharmaceuticals' failed trial, noting differences in drug pharmacology and trial design. UBS initiated coverage with a Buy rating, projecting $3.3B in sales by 2035. RBC Capital reiterated its Outperform rating. OCUL plans to submit an NDA for Axpaxli in Q4 2026.
1 min readNeedham reaffirmed a Buy rating on Ocular Therapeutix (OCUL) with an $18 price target, suggesting a 162% upside from the Oct 16 close of $6.87. The firm highlights Axpaxli's strong market position and promising clinical data, including extended dosing intervals of 9-12 months.
1 min readOcular Therapeutix announced that Sanjay Nayak resigned as Chief Strategy Officer, effective October 16, 2026, to become CEO of a private company. No replacement was disclosed.
1 min readOCULAR THERAPEUTIX, INC (OCUL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 14, 2026, Sanjay Nayak, M.B.B.S., Ph.D., Chief Strategy Officer of Ocular Therapeutix, Inc. (the “Company”), not
1 min readUBS initiated coverage on Ocular Therapeutix (OCUL) with a buy rating and $14 price target, citing Axpaxli's potential in retinal therapy. The stock trades at $7.54, with UBS modeling $3.3B in 2035 sales. Positive Phase 3 trial results and regulatory updates are expected. Analysts remain optimistic despite competitor setbacks and delayed trial readouts.
2 min readRaymond James analysts identified top healthcare stocks, including Dyne Therapeutics (DYNE-251 data expected 4Q25), Ocular Therapeutix (SOL-R enrollment visibility improving), Trevi Therapeutics (Phase 2b readout in 1H25), and Tyra Biosciences (Phase 2 data in 2026). All are rated Strong Buy or Outperform.
3 min readOcular Therapeutix's (OCUL) CDO Peter Kaiser sold 9,990 shares for $70,429 on Oct 2, 2026, at an average price of $7.05. The sale was automatic to cover tax obligations. OCUL shares are down 40% YTD, trading near a 52-week low. Analysts see potential, with targets up to $34. The company is progressing with FDA meetings for its wAMD drug candidate.
1 min readOcular Therapeutix Inc (OCUL) shares fell 5% on Thursday, on track for their worst week since April 2024, after rivals Kodiak Sciences and 4D Molecular Therapeutics posted positive updates in the wet AMD market. OCUL's lead drug, AXPAXLI, remains on track for FDA filing in Q4 2026. Analysts see potential but shares have dropped 40% YTD.
2 min readOcular Therapeutix (OCUL) shares dropped 22% as competitors Kodiak Sciences (KOD) and 4D Molecular Therapeutics (FDMT) reported positive updates on their wet AMD treatments. KOD's DAYBREAK study met goals, while FDMT's 4D-150 showed lasting benefits. OCUL's AXPAXLI is in development, with FDA filing planned for late 2026.
2 min read
